Global Measurable Residual Disease Testing Market 2026 by Company, Regions, Type and Application, Forecast to 2032

1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Classification of Measurable Residual Disease Testing by Type
  • 1.3.1 Overview: Global Measurable Residual Disease Testing Market Size by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 Global Measurable Residual Disease Testing Consumption Value Market Share by Type in 2025
  • 1.3.3 Flow Cytometry
  • 1.3.4 Polymerase Chain Reaction (PCR)
  • 1.3.5 Next-Generation Sequencing (NGS)
  • 1.3.6 Other
• 1.4 Global Measurable Residual Disease Testing Market by Application
  • 1.4.1 Overview: Global Measurable Residual Disease Testing Market Size by Application: 2021 Versus 2025 Versus 2032
  • 1.4.2 Hematological Malignancies
  • 1.4.3 Leukemia
  • 1.4.4 Lymphoma
  • 1.4.5 Solid Tumors
  • 1.4.6 Other
• 1.5 Global Measurable Residual Disease Testing Market Size & Forecast
• 1.6 Global Measurable Residual Disease Testing Market Size and Forecast by Region
  • 1.6.1 Global Measurable Residual Disease Testing Market Size by Region: 2021 VS 2025 VS 2032
  • 1.6.2 Global Measurable Residual Disease Testing Market Size by Region, (2021-2032)
  • 1.6.3 North America Measurable Residual Disease Testing Market Size and Prospect (2021-2032)
  • 1.6.4 Europe Measurable Residual Disease Testing Market Size and Prospect (2021-2032)
  • 1.6.5 Asia-Pacific Measurable Residual Disease Testing Market Size and Prospect (2021-2032)
  • 1.6.6 South America Measurable Residual Disease Testing Market Size and Prospect (2021-2032)
  • 1.6.7 Middle East & Africa Measurable Residual Disease Testing Market Size and Prospect (2021-2032)

2 Company Profiles

• 2.1 Adaptive Biotechnologies Corporation
  • 2.1.1 Adaptive Biotechnologies Corporation Details
  • 2.1.2 Adaptive Biotechnologies Corporation Major Business
  • 2.1.3 Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Product and Solutions
  • 2.1.4 Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Adaptive Biotechnologies Corporation Recent Developments and Future Plans
• 2.2 ArcherDX, Inc. (Invitae Corporation)
  • 2.2.1 ArcherDX, Inc. (Invitae Corporation) Details
  • 2.2.2 ArcherDX, Inc. (Invitae Corporation) Major Business
  • 2.2.3 ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Product and Solutions
  • 2.2.4 ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 2.2.5 ArcherDX, Inc. (Invitae Corporation) Recent Developments and Future Plans
• 2.3 Asuragen
  • 2.3.1 Asuragen Details
  • 2.3.2 Asuragen Major Business
  • 2.3.3 Asuragen Measurable Residual Disease Testing Product and Solutions
  • 2.3.4 Asuragen Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 2.3.5 Asuragen Recent Developments and Future Plans
• 2.4 Arup Laboratories
  • 2.4.1 Arup Laboratories Details
  • 2.4.2 Arup Laboratories Major Business
  • 2.4.3 Arup Laboratories Measurable Residual Disease Testing Product and Solutions
  • 2.4.4 Arup Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 2.4.5 Arup Laboratories Recent Developments and Future Plans
• 2.5 Bio-Rad Laboratories
  • 2.5.1 Bio-Rad Laboratories Details
  • 2.5.2 Bio-Rad Laboratories Major Business
  • 2.5.3 Bio-Rad Laboratories Measurable Residual Disease Testing Product and Solutions
  • 2.5.4 Bio-Rad Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 2.5.5 Bio-Rad Laboratories Recent Developments and Future Plans
• 2.6 Cergentis B.V.
  • 2.6.1 Cergentis B.V. Details
  • 2.6.2 Cergentis B.V. Major Business
  • 2.6.3 Cergentis B.V. Measurable Residual Disease Testing Product and Solutions
  • 2.6.4 Cergentis B.V. Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 2.6.5 Cergentis B.V. Recent Developments and Future Plans
• 2.7 F. Hoffmann- La Roche Ltd
  • 2.7.1 F. Hoffmann- La Roche Ltd Details
  • 2.7.2 F. Hoffmann- La Roche Ltd Major Business
  • 2.7.3 F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Product and Solutions
  • 2.7.4 F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 2.7.5 F. Hoffmann- La Roche Ltd Recent Developments and Future Plans
• 2.8 Guardant Health
  • 2.8.1 Guardant Health Details
  • 2.8.2 Guardant Health Major Business
  • 2.8.3 Guardant Health Measurable Residual Disease Testing Product and Solutions
  • 2.8.4 Guardant Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 2.8.5 Guardant Health Recent Developments and Future Plans
• 2.9 ICON plc
  • 2.9.1 ICON plc Details
  • 2.9.2 ICON plc Major Business
  • 2.9.3 ICON plc Measurable Residual Disease Testing Product and Solutions
  • 2.9.4 ICON plc Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 2.9.5 ICON plc Recent Developments and Future Plans
• 2.10 Invivoscribe
  • 2.10.1 Invivoscribe Details
  • 2.10.2 Invivoscribe Major Business
  • 2.10.3 Invivoscribe Measurable Residual Disease Testing Product and Solutions
  • 2.10.4 Invivoscribe Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 2.10.5 Invivoscribe Recent Developments and Future Plans
• 2.11 Laboratory Corporation of America Holdings
  • 2.11.1 Laboratory Corporation of America Holdings Details
  • 2.11.2 Laboratory Corporation of America Holdings Major Business
  • 2.11.3 Laboratory Corporation of America Holdings Measurable Residual Disease Testing Product and Solutions
  • 2.11.4 Laboratory Corporation of America Holdings Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 2.11.5 Laboratory Corporation of America Holdings Recent Developments and Future Plans
• 2.12 Mission Bio
  • 2.12.1 Mission Bio Details
  • 2.12.2 Mission Bio Major Business
  • 2.12.3 Mission Bio Measurable Residual Disease Testing Product and Solutions
  • 2.12.4 Mission Bio Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 2.12.5 Mission Bio Recent Developments and Future Plans
• 2.13 Natera, Inc.
  • 2.13.1 Natera, Inc. Details
  • 2.13.2 Natera, Inc. Major Business
  • 2.13.3 Natera, Inc. Measurable Residual Disease Testing Product and Solutions
  • 2.13.4 Natera, Inc. Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 2.13.5 Natera, Inc. Recent Developments and Future Plans
• 2.14 NeoGenomics Laboratories
  • 2.14.1 NeoGenomics Laboratories Details
  • 2.14.2 NeoGenomics Laboratories Major Business
  • 2.14.3 NeoGenomics Laboratories Measurable Residual Disease Testing Product and Solutions
  • 2.14.4 NeoGenomics Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 2.14.5 NeoGenomics Laboratories Recent Developments and Future Plans
• 2.15 Opko Health
  • 2.15.1 Opko Health Details
  • 2.15.2 Opko Health Major Business
  • 2.15.3 Opko Health Measurable Residual Disease Testing Product and Solutions
  • 2.15.4 Opko Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 2.15.5 Opko Health Recent Developments and Future Plans
• 2.16 Quest Diagnostics Incorporated
  • 2.16.1 Quest Diagnostics Incorporated Details
  • 2.16.2 Quest Diagnostics Incorporated Major Business
  • 2.16.3 Quest Diagnostics Incorporated Measurable Residual Disease Testing Product and Solutions
  • 2.16.4 Quest Diagnostics Incorporated Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 2.16.5 Quest Diagnostics Incorporated Recent Developments and Future Plans
• 2.17 Sysmex Corporation
  • 2.17.1 Sysmex Corporation Details
  • 2.17.2 Sysmex Corporation Major Business
  • 2.17.3 Sysmex Corporation Measurable Residual Disease Testing Product and Solutions
  • 2.17.4 Sysmex Corporation Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 2.17.5 Sysmex Corporation Recent Developments and Future Plans
• 2.18 Genetron Health
  • 2.18.1 Genetron Health Details
  • 2.18.2 Genetron Health Major Business
  • 2.18.3 Genetron Health Measurable Residual Disease Testing Product and Solutions
  • 2.18.4 Genetron Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
  • 2.18.5 Genetron Health Recent Developments and Future Plans

3 Market Competition, by Players

• 3.1 Global Measurable Residual Disease Testing Revenue and Share by Players (2021-2026)
• 3.2 Market Share Analysis (2025)
  • 3.2.1 Market Share of Measurable Residual Disease Testing by Company Revenue
  • 3.2.2 Top 3 Measurable Residual Disease Testing Players Market Share in 2025
  • 3.2.3 Top 6 Measurable Residual Disease Testing Players Market Share in 2025
• 3.3 Measurable Residual Disease Testing Market: Overall Company Footprint Analysis
  • 3.3.1 Measurable Residual Disease Testing Market: Region Footprint
  • 3.3.2 Measurable Residual Disease Testing Market: Company Product Type Footprint
  • 3.3.3 Measurable Residual Disease Testing Market: Company Product Application Footprint
• 3.4 New Market Entrants and Barriers to Market Entry
• 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

• 4.1 Global Measurable Residual Disease Testing Consumption Value and Market Share by Type (2021-2026)
• 4.2 Global Measurable Residual Disease Testing Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

• 5.1 Global Measurable Residual Disease Testing Consumption Value Market Share by Application (2021-2026)
• 5.2 Global Measurable Residual Disease Testing Market Forecast by Application (2027-2032)

6 North America

• 6.1 North America Measurable Residual Disease Testing Consumption Value by Type (2021-2032)
• 6.2 North America Measurable Residual Disease Testing Market Size by Application (2021-2032)
• 6.3 North America Measurable Residual Disease Testing Market Size by Country
  • 6.3.1 North America Measurable Residual Disease Testing Consumption Value by Country (2021-2032)
  • 6.3.2 United States Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
  • 6.3.3 Canada Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
  • 6.3.4 Mexico Measurable Residual Disease Testing Market Size and Forecast (2021-2032)

7 Europe

• 7.1 Europe Measurable Residual Disease Testing Consumption Value by Type (2021-2032)
• 7.2 Europe Measurable Residual Disease Testing Consumption Value by Application (2021-2032)
• 7.3 Europe Measurable Residual Disease Testing Market Size by Country
  • 7.3.1 Europe Measurable Residual Disease Testing Consumption Value by Country (2021-2032)
  • 7.3.2 Germany Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
  • 7.3.3 France Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
  • 7.3.4 United Kingdom Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
  • 7.3.5 Russia Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
  • 7.3.6 Italy Measurable Residual Disease Testing Market Size and Forecast (2021-2032)

8 Asia-Pacific

• 8.1 Asia-Pacific Measurable Residual Disease Testing Consumption Value by Type (2021-2032)
• 8.2 Asia-Pacific Measurable Residual Disease Testing Consumption Value by Application (2021-2032)
• 8.3 Asia-Pacific Measurable Residual Disease Testing Market Size by Region
  • 8.3.1 Asia-Pacific Measurable Residual Disease Testing Consumption Value by Region (2021-2032)
  • 8.3.2 China Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
  • 8.3.3 Japan Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
  • 8.3.4 South Korea Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
  • 8.3.5 India Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
  • 8.3.6 Southeast Asia Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
  • 8.3.7 Australia Measurable Residual Disease Testing Market Size and Forecast (2021-2032)

9 South America

• 9.1 South America Measurable Residual Disease Testing Consumption Value by Type (2021-2032)
• 9.2 South America Measurable Residual Disease Testing Consumption Value by Application (2021-2032)
• 9.3 South America Measurable Residual Disease Testing Market Size by Country
  • 9.3.1 South America Measurable Residual Disease Testing Consumption Value by Country (2021-2032)
  • 9.3.2 Brazil Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
  • 9.3.3 Argentina Measurable Residual Disease Testing Market Size and Forecast (2021-2032)

10 Middle East & Africa

• 10.1 Middle East & Africa Measurable Residual Disease Testing Consumption Value by Type (2021-2032)
• 10.2 Middle East & Africa Measurable Residual Disease Testing Consumption Value by Application (2021-2032)
• 10.3 Middle East & Africa Measurable Residual Disease Testing Market Size by Country
  • 10.3.1 Middle East & Africa Measurable Residual Disease Testing Consumption Value by Country (2021-2032)
  • 10.3.2 Turkey Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
  • 10.3.3 Saudi Arabia Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
  • 10.3.4 UAE Measurable Residual Disease Testing Market Size and Forecast (2021-2032)

11 Market Dynamics

• 11.1 Measurable Residual Disease Testing Market Drivers
• 11.2 Measurable Residual Disease Testing Market Restraints
• 11.3 Measurable Residual Disease Testing Trends Analysis
• 11.4 Porters Five Forces Analysis
  • 11.4.1 Threat of New Entrants
  • 11.4.2 Bargaining Power of Suppliers
  • 11.4.3 Bargaining Power of Buyers
  • 11.4.4 Threat of Substitutes
  • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

• 12.1 Measurable Residual Disease Testing Industry Chain
• 12.2 Measurable Residual Disease Testing Upstream Analysis
• 12.3 Measurable Residual Disease Testing Midstream Analysis
• 12.4 Measurable Residual Disease Testing Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology
• 14.2 Research Process and Data Source